Nalidixic acid plus sodium citrate twice daily in the treatment of acute urinary tract infection. Swedish Collaborative Study Group.

Abstract

Negram-Citrat (0.66 g nalidixic acid plus 4 g sodium citrate, NAC) twice daily for five days was evaluated in 257 women with symptoms of acute lower urinary tract infection and nalidixic acid sensitive bacteriuria. At two days post-treatment 85% of the patients were abacteriuric while nalidixic acid resistant Escherichia coli bacteriuria was present in five %. Side effects of NAC were usually mild and transient and resulted in interruption of medication in three % of the patients and visual disturbances were volunteered by 1.6%. At follow-up one month after treatment bacteriuria had recurred in 18% of the patients immediately cured, thus resulting in an overall success rate of 70%. Of the 35 recurring strains three (1 E. coli, 2 Staphylococcus epidermidis) were nalidixic acid resistant.

• Journal: Scandinavian journal of primary health care (Scand J Prim Health Care) Vol. 6 Issue 1 Pg. 59-63 (Feb 1988) ISSN: 0281-3432 [Print] United States
• PMID: 3281205 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• 4-Quinolones
• Anti-Infective Agents
• Anti-Infective Agents, Urinary
• Drug Combinations
• Nalidixic Acid
• citrated nalidixic acid

Topics

• 4-Quinolones
• Acute Disease
• Adolescent
• Adult
• Aged
• Anti-Infective Agents
• Anti-Infective Agents, Urinary (administration & dosage, adverse effects, therapeutic use)
• Bacteriuria (drug therapy)
• Clinical Trials as Topic
• Drug Combinations
• Drug Resistance, Microbial
• Female
• Humans
• Middle Aged
• Nalidixic Acid (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Recurrence
• Urinary Tract Infections (drug therapy)